{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:27:18Z","timestamp":1787750838947,"version":"build-2784847793"},"reference-count":119,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic kidney disease (CKD) is a growing global health burden, strongly associated with cardiovascular disease, the leading cause of mortality in this population. Dyslipidemia is a key metabolic abnormality in CKD, but traditional lipid measures such as total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides often fail to capture the complexity of lipid disturbances in CKD and after kidney transplantation. Apolipoproteins have emerged as more reliable markers of cardiovascular and renal risk. Elevated apolipoprotein B (ApoB), reduced apolipoprotein A1 (ApoA1), and a higher ApoB\/ApoA1 ratio are linked to CKD progression, cardiovascular events, and post-transplant complications, including post-transplant diabetes mellitus. Lipoprotein(a), a genetically determined atherogenic lipoprotein, accumulates in CKD due to impaired clearance and further increases cardiovascular risk. Other apolipoproteins, such as APOL1 and APOE, modulate CKD susceptibility through lipid-dependent and independent mechanisms. In addition, proprotein convertase subtilisin\/kexin type 9 (PCSK9) has been identified as an important regulator of lipid metabolism, and PCSK9 inhibitors may represent a promising therapeutic option, though evidence in advanced CKD and transplant recipients is still limited, especially regarding their effects on apolipoproteins. This review summarizes current evidence on apolipoproteins and PCSK9 in CKD and transplantation, with attention to their potential as biomarkers and therapeutic targets.<\/jats:p>","DOI":"10.3390\/ijms26199664","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:53:37Z","timestamp":1759492417000},"page":"9664","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Apolipoproteins in Chronic Kidney Disease and Kidney Transplant: A Long Unfinished Story"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2742-237X","authenticated-orcid":false,"given":"Carmine","family":"Secondulfo","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8499-5428","authenticated-orcid":false,"given":"Carmine","family":"Izzo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4540-1049","authenticated-orcid":false,"given":"Nicoletta","family":"Vecchione","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9453-7258","authenticated-orcid":false,"given":"Gianmarco","family":"Minelli","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Barra","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Molinaro","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-9136","authenticated-orcid":false,"given":"Luca","family":"Apicella","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Transplant, Salerno University Hospital \u201cSan Giovanni di Dio e Ruggid\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candida","family":"Iacuzzo","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Transplant, Salerno University Hospital \u201cSan Giovanni di Dio e Ruggid\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3899-9557","authenticated-orcid":false,"given":"Sarah","family":"Hamzeh","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5082-9499","authenticated-orcid":false,"given":"Maria","family":"Amicone","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6409-3504","authenticated-orcid":false,"given":"Massimo","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0845-1194","authenticated-orcid":false,"given":"Giancarlo","family":"Bilancio","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, Regional, and National Burden of Chronic Kidney Disease, 1990\u20132017: A Systematic Analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting Life Expectancy, Years of Life Lost, and All-Cause and Cause-Specific Mortality for 250 Causes of Death: Reference and Alternative Scenarios for 2016\u201340 for 195 Countries and Territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00041552-200005000-00011","article-title":"Genes and Renal Disease","volume":"9","author":"Freedman","year":"2000","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1523-1755.2001.00487.x","article-title":"Effect of Lipid Reduction on the Progression of Renal Disease: A Meta-Analysis","volume":"59","author":"Fried","year":"2001","journal-title":"Kidney Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1523-1755.2000.00165.x","article-title":"Plasma Lipids and Risk of Developing Renal Dysfunction: The Atherosclerosis Risk in Communities Study","volume":"58","author":"Muntner","year":"2000","journal-title":"Kidney Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.metabol.2016.11.003","article-title":"An Association of Metabolic Syndrome and Chronic Kidney Disease from a 10-Year Prospective Cohort Study","volume":"67","author":"Huh","year":"2017","journal-title":"Metabolism"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.291.7.844","article-title":"Predictors of New-Onset Kidney Disease in a Community-Based Population","volume":"291","author":"Fox","year":"2004","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrneph.2009.184","article-title":"An Update on the Lipid Nephrotoxicity Hypothesis","volume":"5","author":"Ruan","year":"2009","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s11739-020-02276-5","article-title":"Genetic and Nutritional Factors Determining Circulating Levels of Lipoprotein(a): Results of the \u201cMontignoso Study\u201d","volume":"15","author":"Sereni","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1017\/S0007114507201722","article-title":"The Lipoprotein\/Lipid Profile Is Modulated by a Gene-Diet Interaction Effect between Polymorphisms in the Liver X Receptor-Alpha and Dietary Cholesterol Intake in French-Canadians","volume":"97","author":"Robitaille","year":"2007","journal-title":"Br. J. Nutr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2025.05.006","article-title":"Mechanisms and Applications of Apolipoproteins and Apolipoprotein Mimetic Peptides: Common Pathways in Cardiovascular Disease and Cancer","volume":"113","author":"Delk","year":"2025","journal-title":"Semin. Cancer Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41569-024-01111-0","article-title":"Apolipoprotein B-Containing Lipoproteins in Atherogenesis","volume":"22","author":"Packard","year":"2025","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1046\/j.1523-1755.63.s84.34.x","article-title":"Hypertriglyceridemia in Patients with Chronic Renal Failure: Possible Mechanisms","volume":"63","author":"Prinsen","year":"2003","journal-title":"Kidney Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"119146","DOI":"10.1016\/j.atherosclerosis.2025.119146","article-title":"The Vicious Circle of Chronic Kidney Disease and Hypertriglyceridemia: What Is First, the Hen or the Egg?","volume":"403","author":"Tramontano","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_16","first-page":"185","article-title":"Serum Lipid Profile Constituents as Markers of Cardiovascular Morbidity in Patients on Chronic Hemodialysis","volume":"1","author":"Kirmizis","year":"2007","journal-title":"Biomark. Insights"},{"key":"ref_17","first-page":"e21506","article-title":"The Study of Pattern of Lipid Profile in Chronic Kidney Disease Patients on Conservative Management and Hemodialysis: A Comparative Study","volume":"14","author":"Saini","year":"2022","journal-title":"Cureus"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Stepanova, N. (2024). Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes. Biomedicines, 12.","DOI":"10.3390\/biomedicines12102377"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2215\/CJN.07320619","article-title":"Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD","volume":"15","author":"Staplin","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1093\/ndt\/gfr795","article-title":"Association of Apolipoprotein A1 and B with Kidney Function and Chronic Kidney Disease in Two Multiethnic Population Samples","volume":"27","author":"Goek","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/clinchem\/hvab140","article-title":"ApoB vs Non-HDL-C vs LDL-C as Markers of Cardiovascular Disease","volume":"67","author":"Sniderman","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/jama.2020.5685","article-title":"Lipids and Lipoproteins in 2020","volume":"324","author":"Ference","year":"2020","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Xu, Y., Liu, B., Lin, L., Lei, F., Sun, T., Zhang, X., Song, X., Huang, X., Zeng, Q., and Cai, J. (2023). The Association of Apolipoprotein B with Chronic Kidney Disease in the Chinese Population. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1083614"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","article-title":"Lipids, Lipoproteins, and Apolipoproteins as Risk Markers of Myocardial Infarction in 52 Countries (the INTERHEART Study): A Case-Control Study","volume":"372","author":"McQueen","year":"2008","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Valado, A., Cunha, M., and Pereira, L. (2024). Biomarkers and Seaweed-Based Nutritional Interventions in Metabolic Syndrome: A Comprehensive Review. Mar. Drugs, 22.","DOI":"10.3390\/md22120550"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"840","DOI":"10.2215\/CJN.09830915","article-title":"Apoprotein B\/Apoprotein A-1 Ratio and Mortality among Prevalent Dialysis Patients","volume":"11","author":"Sato","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1681\/ASN.2013080816","article-title":"HDL Cholesterol, Apolipoproteins, and Cardiovascular Risk in Hemodialysis Patients","volume":"26","author":"Silbernagel","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.09320913","article-title":"Relation of Serum Lipids and Lipoproteins with Progression of CKD: The CRIC Study","volume":"9","author":"Rahman","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/00365599.2011.644635","article-title":"Impact of the Apolipoprotein B\/Apolipoprotein A-I Ratio on Renal Outcome in Immunoglobulin A Nephropathy","volume":"46","author":"Lundberg","year":"2012","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/transplantology3020020","article-title":"Dyslipidemia in Renal Transplant Recipients","volume":"3","author":"Chmielnicka","year":"2022","journal-title":"Transplantology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1172\/JCI116544","article-title":"Impaired Fatty Acid Metabolism in Familial Combined Hyperlipidemia. A Mechanism Associating Hepatic Apolipoprotein B Overproduction and Insulin Resistance","volume":"92","author":"Shoulders","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Malyala, R., Rapi, L., Nash, M.M., and Prasad, G.V.R. (2019). Serum Apolipoprotein B and A1 Concentrations Predict Late-Onset Posttransplant Diabetes Mellitus in Prevalent Adult Kidney Transplant Recipients. Can. J. Kidney Health Dis., 6.","DOI":"10.1177\/2054358119850536"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Gao, L., Zhang, Y., Wang, X., and Dong, H. (2021). Association of Apolipoproteins A1 and B with Type 2 Diabetes and Fasting Blood Glucose: A Cross-Sectional Study. BMC Endocr. Disord., 21.","DOI":"10.1186\/s12902-021-00726-5"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): Resurrected by Genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/ndt\/gft080","article-title":"Uraemic Dyslipidaemia Revisited: Role of High-Density Lipoprotein","volume":"28","author":"Speer","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","article-title":"Dyslipidemia of Chronic Renal Failure: The Nature, Mechanisms, and Potential Consequences","volume":"290","author":"Vaziri","year":"2006","journal-title":"Am. J. Physiol-Ren. Physiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1053\/ajkd.2001.27384","article-title":"Abnormalities in Uremic Lipoprotein Metabolism and Its Impact on Cardiovascular Disease","volume":"38","author":"Quaschning","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0272-6386(00)70255-1","article-title":"Atherogenic Lipoprotein Phenotype in End-Stage Renal Failure: Origin and Extent of Small Dense Low-Density Lipoprotein Formation","volume":"35","author":"Deighan","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The Role of Lipoprotein (a) in Chronic Kidney Disease: Thematic Review Series: Lipoprotein (a): Coming of Age at Last","volume":"59","author":"Hopewell","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1159\/000187104","article-title":"Increased Lipoprotein (a) Levels in Subjects with Chronic Renal Failure on Hemodialysis","volume":"62","author":"Barbagallo","year":"2008","journal-title":"Nephron"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a Cause of Cardiovascular Disease: Insights from Epidemiology, Genetics, and Biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/ATVBAHA.117.309920","article-title":"Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease","volume":"37","author":"Bajaj","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/sj.ki.5002131","article-title":"In Vivo Turnover Study Demonstrates Diminished Clearance of Lipoprotein(a) in Hemodialysis Patients","volume":"71","author":"Frischmann","year":"2007","journal-title":"Kidney Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/joim.20027","article-title":"Lipoprotein(a) Concentrations and Cardiovascular Disease in Patients with Chronic Kidney Disease: Results from the German Chronic Kidney Disease Study","volume":"296","author":"Gruber","year":"2024","journal-title":"J. Intern. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1053\/j.jrn.2004.10.003","article-title":"Dyslipidemia and Nephrotic Syndrome: Recent Advances","volume":"15","author":"Kronenberg","year":"2005","journal-title":"J. Ren. Nutr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","article-title":"Disorders of Lipid Metabolism in Nephrotic Syndrome: Mechanisms and Consequences","volume":"90","author":"Vaziri","year":"2016","journal-title":"Kidney Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0026-0495(90)90074-M","article-title":"Low-Density Lipoprotein Metabolism in the Nephrotic Syndrome","volume":"39","author":"Warwick","year":"1990","journal-title":"Metabolism"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ndt\/gft439","article-title":"Role of PCSK9 and IDOL in the Pathogenesis of Acquired LDL Receptor Deficiency and Hypercholesterolemia in Nephrotic Syndrome","volume":"29","author":"Liu","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(96)90026-8","article-title":"Lipoprotein(a) in Renal Disease","volume":"27","author":"Kronenberg","year":"1996","journal-title":"Am. J. Kidney Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1046\/j.1523-1755.1999.00489.x","article-title":"Lipoprotein(a) Levels in Relation to Albumin Concentration in Childhood Nephrotic Syndrome","volume":"55","author":"Noto","year":"1999","journal-title":"Kidney Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1159\/000187400","article-title":"Lipoprotein (a) Levels in End-Stage Renal Failure and Renal Transplantation","volume":"64","author":"Barbagallo","year":"2008","journal-title":"Nephron"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0272-6386(96)90034-7","article-title":"Low-Density Lipoprotein Particle Size Distribution in End-Stage Renal Disease Treated with Hemodialysis or Peritoneal Dialysis","volume":"27","author":"Lee","year":"1996","journal-title":"Am. J. Kidney Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrneph.2010.68","article-title":"Cardiovascular Risk in the Peritoneal Dialysis Patient","volume":"6","author":"Krediet","year":"2010","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/089686080902902S28","article-title":"Insulin Resistance and Glucose Homeostasis in Peritoneal Dialysis","volume":"29","author":"Fortes","year":"2009","journal-title":"Perit. Dial. Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1046\/j.1523-1755.1998.00024.x","article-title":"Compositional and Functional Changes of Low-Density Lipoprotein during Hemodialysis in Patients with ESRD1","volume":"54","author":"Ambrosch","year":"1998","journal-title":"Kidney Int."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Barbagallo, C.M., Cefal\u00f9, A.B., Giammanco, A., Noto, D., Caldarella, R., Ciaccio, M., Averna, M.R., and Nardi, E. (2021). Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation. Life, 11.","DOI":"10.3390\/life11040315"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/0026-0495(91)90067-7","article-title":"Lipoprotein-Apolipoprotein Changes in Renal Transplant Recipients: A 2-Year Follow-Up","volume":"40","author":"Cassader","year":"1991","journal-title":"Metabolism"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"\u015aledzi\u0144ski, M., Go\u0142\u0119biewska, J., and Mika, A. (2024). The Long-Term Effect of Kidney Transplantation on the Serum Fatty Acid Profile. Nutrients, 16.","DOI":"10.3390\/nu16193319"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00007890-199001000-00013","article-title":"The Effect of the American Heart Association Step One Diet on Hyperlipidemia Following Renal Transplantation","volume":"49","author":"Moore","year":"1990","journal-title":"Transplantation"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/j.atherosclerosis.2020.10.514","article-title":"Effects of Kidney Transplantation on Lipid Profile","volume":"315","author":"Deniz","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Luo, B., Zhong, S., Wang, X., Guo, P., Hou, Y., and Di, W. (2024). Management of Blood Lipids in Post-Kidney Transplant Patients: A Systematic Review and Network Meta-Analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1440875"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1073\/pnas.1522913113","article-title":"APOL1 Kidney Disease Risk Variants Cause Cytotoxicity by Depleting Cellular Potassium and Inducing Stress-Activated Protein Kinases","volume":"113","author":"Olabisi","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-physiol-021119-034345","article-title":"APOL1 and Kidney Disease: From Genetics to Biology","volume":"82","author":"Friedman","year":"2020","journal-title":"Annu. Rev. Physiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e51185","DOI":"10.7554\/eLife.51185","article-title":"Apolipoprotein L-1 Renal Risk Variants Form Active Channels at the Plasma Membrane Driving Cytotoxicity","volume":"9","author":"Giovinazzo","year":"2020","journal-title":"eLife"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2215\/CJN.15161219","article-title":"APOL1 Nephropathy: From Genetics to Clinical Applications","volume":"16","author":"Friedman","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2404211","article-title":"APOL1 Bi- and Monoallelic Variants and Chronic Kidney Disease in West Africans","volume":"392","author":"Gbadegesin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1681\/ASN.2019030240","article-title":"APOL1 Kidney Risk Variants and Cardiovascular Disease: An Individual Participant Data Meta-Analysis","volume":"30","author":"Grams","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1139\/cjpp-2021-0150","article-title":"miR-193a as a Potential Mediator of WT-1\/Synaptopodin in the Renoprotective Effect of Losartan on Diabetic Kidney","volume":"100","author":"Gao","year":"2022","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/0004563220983851","article-title":"Plasma miR-193a-3p Can Be a Potential Biomarker for the Diagnosis of Diabetic Nephropathy","volume":"58","author":"Hong","year":"2021","journal-title":"Ann. Clin. Biochem."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Singhal, P.C., and Skorecki, K. (2025). APOL1 Dynamics in Diabetic Kidney Disease and Hypertension. Biomolecules, 15.","DOI":"10.3390\/biom15020205"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1681\/ASN.2017060658","article-title":"APOL1 Genotype and Renal Function of Black Living Donors","volume":"29","author":"Doshi","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/ajt.13223","article-title":"Apolipoprotein L1 Gene Variants in Deceased Organ Donors Are Associated with Renal Allograft Failure","volume":"15","author":"Freedman","year":"2015","journal-title":"Am. J. Transplant."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/TP.0000000000000969","article-title":"APOL1 Genotype and Kidney Transplantation Outcomes from Deceased African American Donors","volume":"100","author":"Freedman","year":"2016","journal-title":"Transplantation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MOT.0000000000000600","article-title":"Apolipoprotein L1 and Kidney Transplantation","volume":"24","author":"Tedla","year":"2019","journal-title":"Curr. Opin. Organ Transplant."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/j.ekir.2023.08.028","article-title":"Novel Therapies in APOL1-Mediated Kidney Disease: From Molecular Pathways to Therapeutic Options","volume":"8","author":"Campbell","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.ekir.2024.06.033","article-title":"Design and Rationale of the Phase 2 Baricitinib Study in Apolipoprotein L1-Mediated Kidney Disease (JUSTICE)","volume":"9","author":"Olabisi","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_77","first-page":"64","article-title":"Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, Following Single- and Multiple-Ascending Doses in Healthy Adults","volume":"4","author":"Egbuna","year":"2024","journal-title":"Glomerular Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.genom.1.1.507","article-title":"Apolipoprotein E: Far More than a Lipid Transport Protein","volume":"1","author":"Mahley","year":"2000","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.2337\/diabetes.49.12.2190","article-title":"APOE Polymorphisms and the Development of Diabetic Nephropathy in Type 1 Diabetes: Results of Case-Control and Family-Based Studies","volume":"49","author":"Araki","year":"2000","journal-title":"Diabetes"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2337\/diacare.21.6.994","article-title":"Apolipoprotein E Polymorphism and Renal Function in German Type 1 and Type 2 Diabetic Patients","volume":"21","author":"Werle","year":"1998","journal-title":"Diabetes Care"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.2337\/diacare.26.8.2416","article-title":"APOE Polymorphism and the Progression of Diabetic Nephropathy in Japanese Subjects with Type 2 Diabetes: Results of a Prospective Observational Follow-up Study","volume":"26","author":"Araki","year":"2003","journal-title":"Diabetes Care"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1399-0004.1995.tb04111.x","article-title":"Increased Frequency of Apolipoprotein Epsilon 2 Allele in Non-Insulin Dependent Diabetic (NIDDM) Patients with Nephropathy","volume":"48","author":"Eto","year":"1995","journal-title":"Clin. Genet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/ajkd.2002.34502","article-title":"Apolipoprotein E Genetic Polymorphism, Remnant Lipoproteins, and Nephropathy in Type 2 Diabetic Patients","volume":"40","author":"Eto","year":"2002","journal-title":"Am. J. Kidney Dis."},{"key":"ref_84","first-page":"368","article-title":"Higher Frequency of Apolipoprotein E2 Allele in Type 2 Diabetic Patients with Nephropathy in Taiwan","volume":"15","author":"Hsieh","year":"2002","journal-title":"J. Nephrol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/ndt\/14.9.2144","article-title":"Association between Apolipoprotein E Polymorphism and Macroalbuminuria in Patients with Non-Insulin Dependent Diabetes Mellitus","volume":"14","author":"Ha","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1093\/ndt\/gfh349","article-title":"Influence of Apolipoprotein E Polymorphisms on Serum Creatinine Levels and Predicted Glomerular Filtration Rate in Healthy Subjects","volume":"19","author":"Liberopoulos","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.ajkd.2004.04.035","article-title":"The Influence of Serum Apolipoprotein E Concentration and Polymorphism on Serum Lipid Parameters in Hemodialysis Patients","volume":"44","author":"Liberopoulos","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/ajkd.1998.v31.pm9531184","article-title":"Apolipoprotein E4 Reduces Risk of Diabetic Nephropathy in Patients with NIDDM","volume":"31","author":"Kimura","year":"1998","journal-title":"Am. J. Kidney Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1046\/j.1523-1755.1999.07107.x","article-title":"Apolipoprotein E Polymorphism and Renal Disease","volume":"71","author":"Oda","year":"1999","journal-title":"Kidney Int."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1076\/opge.23.4.209.13883","article-title":"A Pooled Case-Control Study of the Apolipoprotein E (APOE) Gene in Age-Related Maculopathy","volume":"23","author":"Schmidt","year":"2002","journal-title":"Ophthalmic Genet."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer\u2019s Disease in Late Onset Families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1001\/jama.1994.03520210050031","article-title":"Apolipoprotein E Alleles, Dyslipidemia, and Coronary Heart Disease. The Framingham Offspring Study","volume":"272","author":"Wilson","year":"1994","journal-title":"JAMA"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.ajkd.2003.10.013","article-title":"Apolipoprotein E and Renal Disease","volume":"43","author":"Liberopoulos","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"11820","DOI":"10.1021\/bi026202k","article-title":"Distinct Apolipoprotein E Isoform Preference for Inhibition of Smooth Muscle Cell Migration and Proliferation","volume":"41","author":"Zeleny","year":"2002","journal-title":"Biochemistry"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"49142","DOI":"10.1074\/jbc.M104879200","article-title":"A Protective Role for Kidney Apolipoprotein E. Regulation of Mesangial Cell Proliferation and Matrix Expansion","volume":"276","author":"Chen","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jacl.2016.10.005","article-title":"Plasma PCSK9 Concentrations during the Course of Nondiabetic Chronic Kidney Disease: Relationship with Glomerular Filtration Rate and Lipid Metabolism","volume":"11","author":"Morena","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/IJNRD.S101808","article-title":"Dyslipidemia in Patients with Chronic Kidney Disease: Etiology and Management","volume":"10","author":"Mikolasevic","year":"2017","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/ndt\/gfz122","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9 in Kidney Disease","volume":"34","author":"Schmit","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.transproceed.2023.07.020","article-title":"Safe and Successful Treatment with Pcsk9 Inhibitors in Hypercholesterolemia and Renal Transplantation: A Case Report","volume":"55","year":"2023","journal-title":"Transplant. Proc."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jaccas.2019.09.026","article-title":"Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients","volume":"2","author":"Warden","year":"2020","journal-title":"JACC Case Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40265-025-02158-0","article-title":"Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions","volume":"85","author":"Tramontano","year":"2025","journal-title":"Drugs"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1517\/14712598.2014.902929","article-title":"Efficacy and Safety Profile of Evolocumab (AMG145), an Injectable Inhibitor of the Proprotein Convertase Subtilisin\/Kexin Type 9: The Available Clinical Evidence","volume":"14","author":"Cicero","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1755-5922.12093","article-title":"A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects","volume":"32","author":"Lunven","year":"2014","journal-title":"Cardiovasc. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cpdd.650","article-title":"Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety","volume":"8","author":"Lee","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and Safety of Lipid Lowering by Alirocumab in Chronic Kidney Disease","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney Int."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/dom.13114","article-title":"Efficacy and Safety of Alirocumab in Insulin-Treated Individuals with Type 1 or Type 2 Diabetes and High Cardiovascular Risk: The ODYSSEY DM-INSULIN Randomized Trial","volume":"19","author":"Leiter","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"100483","DOI":"10.1016\/j.xkme.2022.100483","article-title":"Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)","volume":"4","author":"East","year":"2022","journal-title":"Kidney Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jacl.2019.01.011","article-title":"Management of Dyslipidemia in Adult Solid Organ Transplant Recipients","volume":"13","author":"Warden","year":"2019","journal-title":"J. Clin. Lipidol."},{"key":"ref_113","first-page":"315","article-title":"Inhibition of Proprotein Convertase Subtilisin\/Kexin-9 After Kidney Transplant: Single-Center Experience Among Patients with High Cardiovascular Risk","volume":"22","author":"Alotaibi","year":"2024","journal-title":"Exp. Clin. Transplant."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000004942","article-title":"Management of Dyslipidemia with Evolocumab in Kidney Transplant Recipients","volume":"108","author":"Amaro","year":"2024","journal-title":"Transplantation"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Lv, P., Li, Y., Wu, L., Weng, H., Chen, M., Ding, W., and Li, J. (2022). PCSK9 Inhibitors in a Renal Transplant Patient Complicated with Hepatitis B: A Case Report and Literature Review. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.937474"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of Alirocumab on Major Adverse Cardiovascular Events According to Renal Function in Patients with a Recent Acute Coronary Syndrome: Prespecified Analysis from the ODYSSEY OUTCOMES Randomized Clinical Trial","volume":"41","author":"Steg","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ehjcvp\/pvae025","article-title":"Safety of the PCSK9 Inhibitor Alirocumab: Insights from 47 296 Patient-Years of Observation","volume":"10","author":"Goodman","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal Effects of Atorvastatin and Rosuvastatin in Patients with Diabetes Who Have Progressive Renal Disease (PLANET I): A Randomised Clinical Trial","volume":"3","author":"Anzalone","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/eurheartj\/ehad640","article-title":"Mechanisms of Rosuvastatin-Related Acute Kidney Injury Following Cardiac Surgery: The STICS Trial","volume":"45","author":"Wijesurendra","year":"2024","journal-title":"Eur. Heart J."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9664\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:54:36Z","timestamp":1759492476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":119,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms26199664"],"URL":"https:\/\/doi.org\/10.3390\/ijms26199664","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]}}}